Metabolic and cardiovascular effects of ghrelin.
Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, is synthesized as a preprohormone and then proteolytically processed to yield a 28-amino acid peptide. This peptide was originally reported to induce growth hormone release; large evidence, however, has indicated many other physiological activities of ghrelin, including regulation of food intake and energy balance, as well as of lipid and glucose metabolism. Ghrelin receptors have been detected in the hypothalamus and the pituitary, but also in the cardiovascular system, where ghrelin exerts beneficial hemodynamic activities. Ghrelin administration acutely improves endothelial dysfunction by increasing nitric oxide bioavailability and normalizes the altered balance between endothelin-1 and nitric oxide within the vasculature of patients with metabolic syndrome. Other cardiovascular effects of ghrelin include improvement of left ventricular contractility and cardiac output, as well as reduction of arterial pressure and systemic vascular resistance. In addition, antinflammatory and antiapoptotic actions of ghrelin have been reported both in vivo and in vitro. This review summarizes the most recent findings on the metabolic and cardiovascular effects of ghrelin through GH-dependent and -independent mechanisms and the possible role of ghrelin as a therapeutic molecule for treating cardiovascular diseases.
Tesauro
Manfredi
M
Department of Medicina Interna, Università di Tor Vergata, 00133 Rome, Italy.
Schinzari
Francesca
F
Caramanti
Miriam
M
Lauro
Renato
R
Cardillo
Carmine
C
J Cell Biol. 2002 Dec 23;159(6):1029-37
12486113
Am J Physiol Regul Integr Comp Physiol. 2001 May;280(5):R1483-7
11294772
Circulation. 2004 Dec 14;110(24):3674-9
15569841
J Biol Chem. 2002 Feb 15;277(7):5667-74
11724768
Nat Med. 2002 Jul;8(7):643-4
12091883
Circulation. 2005 Nov 8;112(19):2986-92
16260640
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6320-5
18443287
Front Neuroendocrinol. 2004 Apr;25(1):27-68
15183037
Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):133-7
18537600
Endocrinology. 2006 May;147(5):2306-14
16484324
Circulation. 2001 Sep 18;104(12):1430-5
11560861
Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E486-92
15507538
J Pediatr. 2004 Jan;144(1):36-42
14722516
J Clin Endocrinol Metab. 2000 Oct;85(10):3803-7
11061542
Endocr Rev. 2004 Jun;25(3):426-57
15180951
J Clin Endocrinol Metab. 2001 Dec;86(12):5854-9
11739451
J Clin Endocrinol Metab. 2002 Jan;87(1):240-4
11788653
Rev Endocr Metab Disord. 2006 Dec;7(4):237-49
17195943
Nature. 1999 Dec 9;402(6762):656-60
10604470
Proc Nutr Soc. 2008 Aug;67(3):263-9
18452642
J Clin Endocrinol Metab. 2002 Dec;87(12):5625-9
12466363
Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H426-32
18024547
Nat Med. 2009 Jul;15(7):741-5
19503064
Gut. 2005 Jan;54(1):18-24
15591499
J Clin Endocrinol Metab. 2002 Jun;87(6):2988
12050285
J Endocrinol. 2003 Nov;179(2):237-44
14596675
J Clin Endocrinol Metab. 2001 Apr;86(4):1738-45
11297611
Gastroenterology. 2005 Jul;129(1):8-25
16012930
J Clin Invest. 2004 Jul;114(1):57-66
15232612
Br J Pharmacol. 2002 Aug;136(8):1146-52
12163347
Diabetes. 2003 Oct;52(10):2546-53
14514639
Endocrinology. 2004 Jan;145(1):234-42
14551228
J Clin Endocrinol Metab. 2001 Feb;86(2):881-7
11158061
J Clin Endocrinol Metab. 2002 Mar;87(3):1300-8
11889202
J Clin Endocrinol Metab. 2003 Apr;88(4):1537-42
12679436
Diabetes. 2001 Apr;50(4):707-9
11289032
J Endocrinol Invest. 2006 Feb;29(2):115-21
16610236
Metabolism. 2005 Jul;54(7):925-9
15988702
Endocrinology. 2008 Feb;149(2):827-35
18039782
J Endocrinol Invest. 2001 Mar;24(3):RC7-9
11314756
Mol Endocrinol. 1997 Apr;11(4):415-23
9092793
Curr Opin Pharmacol. 2006 Apr;6(2):142-7
16483844
N Engl J Med. 2002 May 23;346(21):1623-30
12023994
Vitam Horm. 2008;77:207-38
17983858
Metabolism. 2003 Nov;52(11):1460-3
14624407
Cardiovasc Res. 2004 Jun 1;62(3):481-8
15158140
J Clin Endocrinol Metab. 2005 Dec;90(12):6448-53
16204363
Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E756-64
17106060
Trends Endocrinol Metab. 2001 Apr;12(3):118-22
11306336
Endocrinology. 2003 Dec;144(12):5184-7
14525914
J Biol Chem. 2005 Jul 1;280(26):25196-201
15899896
Cardiovasc Res. 2006 Jan;69(1):227-35
16226234
FEBS Lett. 2003 Sep 25;552(2-3):105-9
14527669
Endokrynol Pol. 2008 May-Jun;59(3):207-11
18615394
Circulation. 2001 Oct 23;104(17):2034-8
11673342
Endocrinology. 2003 Mar;144(3):754-9
12586750
Clin Endocrinol (Oxf). 2005 Jan;62(1):1-17
15638864
Regul Pept. 2003 Nov 15;116(1-3):101-7
14599721
Hypertension. 2009 Nov;54(5):995-1000
19786648
Nature. 2000 Oct 19;407(6806):908-13
11057670
J Med Chem. 2000 Nov 16;43(23):4370-6
11087562
Trends Endocrinol Metab. 2006 Jan-Feb;17(1):13-8
16309920
J Endocrinol Invest. 2005;28(5 Suppl):23-5
16114271
J Endocrinol. 2002 Oct;175(1):201-9
12379504
Mol Interv. 2002 Dec;2(8):494-503
14993401
Basic Res Cardiol. 2003 Nov;98(6):401-5
14556085
Cell. 2008 Feb 8;132(3):387-96
18267071
Regul Pept. 2005 Aug 15;130(1-2):97-103
15946750
Intern Med. 2006;45(3):127-34
16508225
Br J Pharmacol. 2001 Sep;134(1):143-9
11522606
Circulation. 2004 May 11;109(18):2221-6
15117840